Research ArticleBIOMATERIALS

Percutaneous liquid ablation agent for tumor treatment and drug delivery

See allHide authors and affiliations

Science Translational Medicine  10 Feb 2021:
Vol. 13, Issue 580, eabe3889
DOI: 10.1126/scitranslmed.abe3889

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Advances in ablation

For individuals with hepatocellular carcinoma, percutaneous locoregional therapies can extend the time to liver transplantation. Albadawi et al. developed an ionic liquid–ablative agent named LATTE that could be locally injected into rat, rabbit, and pig livers in vivo under imaging guidance. LATTE coformulated with the chemotherapy drug doxorubicin injected into tumors in rat and rabbit livers ablated the desired regions, uniformly distributed the drug, and could also ablate human liver tumor tissue samples ex vivo. Results support the use of LATTE for percutaneous ablation of solid tumors.

View Full Text

Stay Connected to Science Translational Medicine